Difusão do Conhecimento Através das Diferentes Áreas da Medicina 4

Lais Daiene Cosmoski (Organizadora)



Difusão do Conhecimento Através das Diferentes Áreas da Medicina 4

Lais Daiene Cosmoski (Organizadora)



2019 by Atena Editora Copyright © Atena Editora

Copyright do Texto © 2019 Os Autores

Copyright da Edição © 2019 Atena Editora

Editora Chefe: Profa Dra Antonella Carvalho de Oliveira

Diagramação: Natália Sandrini Edição de Arte: Lorena Prestes Revisão: Os Autores



Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição Creative Commons. Atribuição 4.0 Internacional (CC BY 4.0).

O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.

Conselho Editorial

Ciências Humanas e Sociais Aplicadas

- Prof^a Dr^a Adriana Demite Stephani Universidade Federal do Tocantins
- Prof. Dr. Álvaro Augusto de Borba Barreto Universidade Federal de Pelotas
- Prof. Dr. Alexandre Jose Schumacher Instituto Federal de Educação, Ciência e Tecnologia de Mato Grosso
- Prof. Dr. Antonio Carlos Frasson Universidade Tecnológica Federal do Paraná
- Prof. Dr. Antonio Gasparetto Júnior Instituto Federal do Sudeste de Minas Gerais
- Prof. Dr. Antonio Isidro-Filho Universidade de Brasília
- Prof. Dr. Constantino Ribeiro de Oliveira Junior Universidade Estadual de Ponta Grossa
- Prof^a Dr^a Cristina Gaio Universidade de Lisboa
- Prof. Dr. Devvison de Lima Oliveira Universidade Federal de Rondônia
- Prof. Dr. Edvaldo Antunes de Farias Universidade Estácio de Sá
- Prof. Dr. Eloi Martins Senhora Universidade Federal de Roraima
- Prof. Dr. Fabiano Tadeu Grazioli Universidade Regional Integrada do Alto Uruguai e das Missões
- Prof. Dr. Gilmei Fleck Universidade Estadual do Oeste do Paraná
- Prof^a Dr^a Ivone Goulart Lopes Istituto Internazionele delle Figlie de Maria Ausiliatrice
- Prof. Dr. Julio Candido de Meirelles Junior Universidade Federal Fluminense
- Prof^a Dr^a Keyla Christina Almeida Portela Instituto Federal de Educação, Ciência e Tecnologia de Mato Grosso
- Prof^a Dr^a Lina Maria Goncalves Universidade Federal do Tocantins
- Prof^a Dr^a Natiéli Piovesan Instituto Federal do Rio Grande do Norte
- Prof. Dr. Marcelo Pereira da Silva Universidade Federal do Maranhão
- Prof^a Dr^a Miranilde Oliveira Neves Instituto de Educação, Ciência e Tecnologia do Pará
- Prof^a Dr^a Paola Andressa Scortegagna Universidade Estadual de Ponta Grossa
- Profa Dra Rita de Cássia da Silva Oliveira Universidade Estadual de Ponta Grossa
- Profa Dra Sandra Regina Gardacho Pietrobon Universidade Estadual do Centro-Oeste
- Profa Dra Sheila Marta Carregosa Rocha Universidade do Estado da Bahia
- Prof. Dr. Rui Maia Diamantino Universidade Salvador
- Prof. Dr. Urandi João Rodrigues Junior Universidade Federal do Oeste do Pará
- Prof^a Dr^a Vanessa Bordin Viera Universidade Federal de Campina Grande
- Prof. Dr. Willian Douglas Guilherme Universidade Federal do Tocantins

Ciências Agrárias e Multidisciplinar

- Prof. Dr. Alexandre Igor Azevedo Pereira Instituto Federal Goiano
- Prof. Dr. Antonio Pasqualetto Pontifícia Universidade Católica de Goiás
- Profa Dra Daiane Garabeli Trojan Universidade Norte do Paraná
- Profa Dra Diocléa Almeida Seabra Silva Universidade Federal Rural da Amazônia
- Prof. Dr. Écio Souza Diniz Universidade Federal de Viçosa
- Prof. Dr. Fábio Steiner Universidade Estadual de Mato Grosso do Sul
- Profa Dra Girlene Santos de Souza Universidade Federal do Recôncavo da Bahia
- Prof. Dr. Jorge González Aguilera Universidade Federal de Mato Grosso do Sul
- Prof. Dr. Júlio César Ribeiro Universidade Federal Rural do Rio de Janeiro
- Prof^a Dr^a Raissa Rachel Salustriano da Silva Matos Universidade Federal do Maranhão
- Prof. Dr. Ronilson Freitas de Souza Universidade do Estado do Pará
- Prof. Dr. Valdemar Antonio Paffaro Junior Universidade Federal de Alfenas



Ciências Biológicas e da Saúde

Prof. Dr. Benedito Rodrigues da Silva Neto - Universidade Federal de Goiás

Prof. Dr. Edson da Silva - Universidade Federal dos Vales do Jequitinhonha e Mucuri

Prof^a Dr^a Elane Schwinden Prudêncio - Universidade Federal de Santa Catarina

Prof. Dr. Gianfábio Pimentel Franco - Universidade Federal de Santa Maria

Prof. Dr. José Max Barbosa de Oliveira Junior - Universidade Federal do Oeste do Pará

Prof^a Dr^a Magnólia de Araújo Campos – Universidade Federal de Campina Grande

Prof^a Dr^a Natiéli Piovesan – Instituto Federal do Rio Grande do Norte

Prof^a Dr^a Vanessa Lima Gonçalves - Universidade Estadual de Ponta Grossa

Prof^a Dr^a Vanessa Bordin Viera – Universidade Federal de Campina Grande

Ciências Exatas e da Terra e Engenharias

Prof. Dr. Adélio Alcino Sampaio Castro Machado - Universidade do Porto

Prof. Dr. Alexandre Leite dos Santos Silva - Universidade Federal do Piauí

Profa Dra Carmen Lúcia Voigt - Universidade Norte do Paraná

Prof. Dr. Eloi Rufato Junior - Universidade Tecnológica Federal do Paraná

Prof. Dr. Fabrício Menezes Ramos - Instituto Federal do Pará

Prof. Dr. Juliano Carlo Rufino de Freitas - Universidade Federal de Campina Grande

Prof^a Dr^a Neiva Maria de Almeida – Universidade Federal da Paraíba

Profa Dra Natiéli Piovesan - Instituto Federal do Rio Grande do Norte

Prof. Dr. Takeshy Tachizawa - Faculdade de Campo Limpo Paulista

Dados Internacionais de Catalogação na Publicação (CIP) (eDOC BRASIL, Belo Horizonte/MG)

D569 Difusão do conhecimento através das diferentes áreas da medicina 4 [recurso eletrônico] / Organizadora Lais Daiene Cosmoski. – Ponta Grossa, PR: Atena Editora, 2019. – (Difusão do conhecimento através das diferentes áreas da medicina; v. 4)

Formato: PDF

Requisitos de sistema: Adobe Acrobat Reader

Modo de acesso: World Wide Web

Inclui bibliografia

ISBN 978-85-7247-883-0 DOI 10.22533/at.ed.830192312

Medicina – Pesquisa – Brasil. 2. Saúde - Brasil. 3. Diagnóstico.

I. Cosmoski, Lais Daiene. II. Série.

CDD 610.9

Elaborado por Maurício Amormino Júnior - CRB6/2422

Atena Editora

Ponta Grossa – Paraná - Brasil

<u>www.atenaeditora.com.br</u>

contato@atenaeditora.com.br



APRESENTAÇÃO

Cada vez mais percebemos, que no mundo da ciência, principalmente da área da saúde, nenhuma profissão trabalha sozinha, é necessário que vários profissionais estão envolvidos e engajados em conjunto, prezando pela, prevenção, diagnóstico e tratamento de diversas patologias, visando sempre a qualidade de vida da população em geral.

A Coletânea Nacional "Difusão do Conhecimento Através das Diferentes Áreas da Medicina" é um *e-book* composto por 4 volumes artigos científicos, que abordam relatos de caso, avaliações e pesquisas sobre doenças já conhecidas da sociedade, trata ainda de casos conforme a região demográfica, onde os locais de realização dos estudos estão localizados em nosso país, trata também do desenvolvimento de novas tecnologias para prevenção, diagnóstico e tratamento de algumas patologias.

Abordamos também o lado pessoal e psicológico dos envolvidos nos cuidados dos indivíduos, mostrando que além dos acometidos pelas doenças, aqueles que os cuidam também merecem atenção.

Os artigos elencados neste *e-book* contribuirão para esclarecer que ambas as profissões desempenham papel fundamental e conjunto para manutenção da saúde da população e caminham em paralelo para que a para que a ciência continue evoluindo para estas áreas de conhecimento.

Desejo a todos uma excelente leitura!

Lais Daiene Cosmoski

SUMÁRIO

CAPÍTULO 11
TERRITORIALIZAÇÃO: UMA FERRAMENTA IMPRESCINDÍVEL NA ATENÇÃO BÁSICA PARA O DIAGNÓSTICO DA COMUNIDADE
Ana Carolina Ramalho dos Reis João Gabriel Ferreira Borges Vinhal Luisa Fernandes de Andrade Márcia Kissia de Souza Rosa Maria Paula Lacerda Reis Marthius Campos Oliveira Santos Thiago França de Melo Rocha Marilene Rivany Nunes
DOI 10.22533/at.ed.8301923121
CAPÍTULO 210
TERRITORIALIZAÇÃO DE UMA UNIDADE BÁSICA DE SAÚDE DE PATOS DE MINAS Júlia Alves Campos Carneiro Olímpio Pereira de Melo Neto Marconi Guarienti Anna Luiza Gonçalves Magalhães Vanessa Silva Lima Paulo Vítor Bernardes Sidney Silva Frederico Vilani Vilela Maura Regina Guimarães Rabelo Marilene Rivany Nunes DOI 10.22533/at.ed.8301923122
CAPÍTULO 315
A PERCEPCÃO DO ENSINO DA NEUROLOGIA EM ESTUDANTES DO SEGUNDO SEMESTRE DE MEDICINA DA UNIVERSIDADE DE FORTALEZA Romerio Alves Soares Tiago Augusto Braga Vasconcelos Edilson Lopes de Oliveira Junior Armando Nicodemos Lucena Felinto Guilherme Diógenes Bessa Guilherme Pávero Quináglia Paulo Arthur Silva de Carvalho Luiz Gustavo Costa Neves Francisco Alves Grangeiro Neto Emmily Barbosa da Silva Paulo Heinrich Soares Bomtempo Rafaela Patricia Tavares Silva DOI 10.22533/at.ed.8301923123
CAPÍTULO 4

CAPÍTULO 5
ANÁLISE DA PREVALÊNCIA DO ALEITAMENTO MATERNO EXCLUSIVO NA ÁREA DE ABRANGÊNCIA DA UBS VÁRZEA - PATOS DE MINAS, MG
Henrique Takeshi Pinto Emi Ana Clara Costa Garcia Brenda Viana Valadares Caíque Mortati Martins da Silva Milla Cristie Rodrigues Costa Virgínia Fernandes Fiúza Isadora Sene Marisa Costa e Peixoto Giovana Bertoni Palis Samora João Vítor Resende Andrade DOI 10.22533/at.ed.8301923125
CAPÍTULO 640
ANÁLISE DO PERFIL DE SAÚDE MENTAL EM ACADÊMICOS DE MEDICINA DA UFPE-CAMPUS ACADÊMICO DO AGRESTE
Armando Nicodemos Lucena Felinto Edilson Lopes de Oliveira Junior Romerio Alves Soares Tiago Augusto Braga Vasconcelos Guilherme Diogenes Bessa Hugo montenegro Vieira da Silva Marco Antonio de Lucena Furtado Jessica Alves Soares Pedro Oliveira Conopca Paulo Victor Mendonça de Oliveira Pedro Evangelista Borges Dantas Rafael Cicero de Lima e Silva DOI 10.22533/at.ed.8301923126
CAPÍTULO 742
ANÁLISE DE COMUNIDADE EM UNIDADE BÁSICA DE SAÚDE NO INTERIOR DE MINAS GERAIS COM ENFOQUE EM DIMENSIONAMENTO DE HIPERTENSÃO ARTERIAL SISTÊMICA E DA DIABETES MELLITUS
Plínio Resende de Melo Filho Amanda Abdanur Cruz do Nascimento Ana Luisa Freitas Dias Giovana Vilela Rocha Gabriela Conrado Machado Laura Melo Rosa Maria Flávia Ribeiro Pereira Mariana Alves Mota Marilene Rivany Nunes Mateus Soares Chaves Pedro Augusto Silveira DOI 10.22533/at.ed.8301923127
CAPÍTULO 8
ANÁLISE DOS ESTUDANTES DE MEDICINA EM UM CAMPUS DA UNIVERSIDADE FEDERAL DO PERNAMBUCO SOBRE A ABORDAGEM DE TEMAS DA NEUROLOGIA APLICADOS DURANTE A GRADUAÇÃO
Armando Nicodemos Lucena Felinto Edilson Lopes de Oliveira Junior

Romerio Alves Soares

Tiago Augusto Braga Vasconcelos Guilherme Diogenes Bessa Hugo montenegro Vieira da Silva Marco Antonio de Lucena Furtado Jessica Alves Soares Pedro Oliveira Conopca Paulo Victor Mendonça de Oliveira Pedro Evangelista Borges Dantas
Rafael Cicero de Lima e Silva DOI 10.22533/at.ed.8301923128
CAPÍTULO 9
AFRODESCENDENTE DO RS
Patrícia Maurer
Lyana Feijoó Berro Vanusa Manfredini
Jacqueline da Costa Escobar Piccoli
DOI 10.22533/at.ed.8301923129
CAPÍTULO 105
CONHECIMENTO E PERCEPÇÃO DOS ESTUDANTES DE UMA UNIVERSIDADE PÚBLICA DA CIDADE DE FORTALEZA-CE SOBRE O PAPILOMA VÍRUS HUMANO (HPV)
Erivan de Souza Oliveira
Marcela Feitosa Matos Rayssa Priscilla Costa Reis
Arlandia Cristina Lima Nobre de Morais
DOI 10.22533/at.ed.83019231210
CAPÍTULO 1170
EDUCAÇÃO EM SAÚDE: PROPOSTA DE CAPACITAÇÃO DE AGENTES COMUNITÁRIOS DI SAÚDE NA ESF ÁGUAS LINDAS 2, ANANINDEUA/PA
Érika Maria Carmona Keuffer Cavalleiro de Macedo Erica Furtado Azevedo Coelho
Ivete Moura Seabra de Souza
DOI 10.22533/at.ed.83019231211
CAPÍTULO 128
EDUCAÇÃO EM SAÚDE: UMA PROPOSTA DE RESGATE PARA PACIENTES CADASTRADOS NO PROGRAMA HIPERDIA EM UMA UNIDADE DE SAÚDE DA FAMÍLIA EM CACHOEIRA-BA
Irídio Lima Moura Sônia Elzi Alves dos Santos Sena Pereira
DOI 10.22533/at.ed.83019231212
CAPÍTULO 138
ESTIMULAÇÃO MAGNÉTICA TRANSCRANIANA: UMA ANÁLISE DOS GRUPOS DE PESQUISA NO BRASIL
Hercílio Barbosa Silva Junior Marcos Rassi Fernandes Maria Alves Fernandes
DOI 10.22533/at.ed.83019231213

CAPÍTULO 14100
FATORES ASSOCIADOS À MORTALIDADE DO PACIENTE COM TRAUMATISMO CRANIOENCEFÁLICO MODERADO E GRAVE NA UNIDADE DE TERAPIA INTENSIVA DO HOSPITAL GOVERNADOR CELSO RAMOS
Marina Casagrande do Canto Isabela Scheidt Prazeres
Victor Gabriel Vieira Goncho Eduardo Areias de Oliveira
Laura Gazola Ugioni DOI 10.22533/at.ed.83019231214
CAPÍTULO 15 116
IMPLANTAÇÃO DO "PASSAPORTE DE ESTÍMULOS" PARA BEBÊS SAUDÁVEIS EM UMA ESTRATÉGIA SAÚDE DA FAMÍLIA DE MUNICÍPIO DO NORTE DO BRASIL
Érika Maria Carmona Keuffer Cavalleiro de Macedo Mariane Cordeiro Alves Franco
DOI 10.22533/at.ed.83019231215
CAPÍTULO 16129
MISSÕES DE TELEDERMATOLOGIA EM PALMARES DO SUL
Ana Luíza Fonseca Siqueira Karine Inês Scheidt Flávio Vinicius Costa Ferreira
Vitória D'Ávila Felipe Chitolina Escobal Luísa Nakashima Pereira
Cláudio Roberto Amorim dos Santos Júnior Luísa Gallas Eickhoff
Rodrigo Volf dos Santos Maurício Machado da Rosa Michala dos Santos Corres do Rosa
Michele dos Santos Gomes da Rosa Thais Russomano
DOI 10.22533/at.ed.83019231216
CAPÍTULO 17133
MONITORAMENTO DE ALOANTICORPOS HLA EM PACIENTES RENAIS TRANSPLANTADOS DA REGIÃO NORTE/NOROESTE DO ESTADO DO PARANÁ, SUL DO BRASIL
Ayla Carolina de Almeida Rodrigo Amaral Kulza Sueli Donizete Borelli
DOI 10.22533/at.ed.83019231217
CAPÍTULO 18143
O CENÁRIO DO TRANSPLANTE CARDÍACO NO BRASIL: UM ESTUDO RETROSPECTIVO BASEADOS EM DADOS ELETRÔNICOS
Isadora Galvão Dalenogare Rafaela Silveira Passamani Luiza Paz Cachapuz
Matheus Pavanelo Soliman
Tiago José Nardi Gomes Patrícia de Moraes Costa Padro Augusto Marollo Collo
Pedro Augusto Morello Cella DOI 10.22533/at.ed.83019231218

CAPÍTULO 19155
O USO DA BIOINFORMÁTICA NA CARACTERIZAÇÃO DE PROCESSOS RELEVANTES NO REPARO TECIDUAL NO INFARTO AGUDO DO MIOCÁRDIO COM ELEVAÇÃO DO SEGMENTO-ST
Melissa Kristochek da Silva Marco Antônio De Bastiani
Lucinara Dadda Dias
Marcela Corso Arend Raphael Boesche Guimarães
Melissa Medeiros Markoski
DOI 10.22533/at.ed.83019231219
CAPÍTULO 20171
"PERFIL EPIDEMIOLÓGICO DA EQUISTOSSOMOSE NO BRASIL NO PERÍODO DE 2007 – 2017"
Marlete Corrêa de Faria
José Tadeu Raynal Rocha Filho
DOI 10.22533/at.ed.83019231220
CAPÍTULO 21183
PERFIL EPIDEMIOLÓGICO DOS ACIDENTES OFÍDICOS REGISTRADOS NO MUNICÍPIO DE PORTO NACIONAL - TO NO PERÍODO DE 2015 A 2018
Hugo Felipe Silva Oliveira Vitor Hugo Guimarães Dezuani
Ruan Cayque Silva Oliveira
Mateus Gomes da Silva Filho
Anderson de Oliveira Ireno
Bruna Silva Resende Carina Scolari Gosch
Astério Souza Magalhães Filho
DOI 10.22533/at.ed.83019231221
CAPÍTULO 22198
THE NATURAL HISTORY OF PREGNANCIES WITH PRENATAL DIAGNOSIS OF TRISOMY 18 OF TRISOMY 13: RETROSPECTIVE CASES OF A 23-YEAR EXPERIENCE IN A BRAZILIAN PUBLIC HOSPITAL
Julio Alejandro Peña Duque
Charles Francisco Ferreira
Maria Teresa Vieira Sanseverino
Rejane Gus José Antônio de Azevedo Magalhães
DOI 10.22533/at.ed.83019231222
CAPÍTULO 23216
IMPLANTAÇÃO DO KANBAN COMO INDUTOR DA MELHORA DO FLUXO DOS PACIENTES NA
EMERGÊNCIA DE HOSPITAL GERAL
Luiz Alexandre Essinger
Denise Scofano Diniz Agostinho Manuel da Silva Ascenção
DOI 10.22533/at.ed.83019231223
CAPÍTULO 24
VISITA DOMICILIAR À IDOSA PARA REALIZAÇÃO DE CURATIVO DA ÚLCERA VENOSA E ACOMPANHAMENTO DA CICATRIZAÇÃO
Ananda Borges Ponce Leal

Ana Flávia das Chagas Costa

Roselma Marcele da Silva Alexandre Kawakami
DOI 10.22533/at.ed.83019231224
CAPÍTULO 25234
MALOCLUSÕES NA DENTIÇÃO DECÍDUA DE PRÉ-ESCOLARES NASCIDOS PREMATUROS Fernanda Malheiro Santos Edna Maria de Albuquerque Diniz DOI 10.22533/at.ed.83019231225
CAPÍTULO 26248
EYE AXIS CHECK: APLICATIVO PARA AFERIÇÃO INTRAOPERATÓRIA DO ALINHAMENTO DE IMPLANTES CORNEANOS E INTRAOCULARES EM CIRURGIA OFTALMOLÓGICA PARA CORREÇÃO DO CERATOCONE EDO ASTIGMATISMO Francisco Aécio Fernandes Dias Vinicius José Fernandes Dias Francyelle Samyramis Lourenço Rodrigues João Crispim Moraes Lima Ribeiro DOI 10.22533/at.ed.83019231226
CAPÍTULO 27266
STAINS OF EJACULATED PRE AND POST-VASECTOMY: PURITY AND SUFFICIENT QUANTITY OF RECOVERED DNA AFTER 10 YEARS OF STORAGE Carolina Mautoni Rafael Dias Astolphi Rafael Barrios Mello Jose Arnaldo Soares-Vieira Marcelo Souza Silva Maria Luiza Almeida Prado Oliveira Sousa Eloisa Auler Bittencourt Edna Sadayo Miazato Iwamura DOI 10.22533/at.ed.83019231227
SOBRE A ORGANIZADORA272
ÍNDICE REMISSIVO

Gleiton Ramalho Ferreira

CAPÍTULO 22

THE NATURAL HISTORY OF PREGNANCIES WITH PRENATAL DIAGNOSIS OF TRISOMY 18 OR TRISOMY 13: RETROSPECTIVE CASES OF A 23-YEAR EXPERIENCE IN A BRAZILIAN PUBLIC HOSPITAL

Data de aceite:19/11/2018

Julio Alejandro Peña Duque

Gynecology and obstetrics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

Charles Francisco Ferreira

Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Maria Teresa Vieira Sanseverino

Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Rejane Gus

Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

José Antônio de Azevedo Magalhães

Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.

Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

ABSTRACT: Trisomy 18 (T18) and trisomy 13 (T13) are polymalformative syndromes associated with a high rate of spontaneous abortions, intrauterine death, and short postnatal life. This study describes the overall outcome in a country where the therapeutic interruption of pregnancy is not available. The medical records of women with prenatal diagnosis of T13 or T18 between 1994 and 2017 were analyzed in order to describe their natural outcomes.

Thirteen cases of T13 and 29 cases of T18 were included. The miscarriage rate was 9% for T18 and no cases for T13. Intrauterine fetal death occurred in 46% and 52% of cases for T13 and T18, respectively. The rate of live births for T13 was 54%, and the median survival was one day (95% CI -33.55 - 90.40) and 71% died in the first 24 hours of life. The rate of live births for T18 was 37% and the median survival was two days (95% CI -1.89 - 13.17); 90% of the affected babies died within first week of life. For the affected babies reaching the first year of life and for those who lived longer, multiple invasive and expensive procedures were required, without success in prolonging life beyond 180 days. This large series provides information for professionals and women regarding the natural histories of T13 and T18. Results of this study are consistent with those referenced in the literature, emphasizing the need of structured protocols and guidelines aiming early T13 and T18 diagnosis, prenatal care, gestation/parents follow-up, and counseling processes.

KEYWORDS: Natural history of trisomy, trisomy 13, trisomy 18, prenatal diagnosis, genetic counseling.

INTRODUCTION

During the last decade, new screening methods and protocols for prenatal diagnosis of genetic disorders in the first and second trimesters of pregnancy have been established for the general and the at-risk-profile population. Since then, the aneuploidy detection has increased, mainly for trisomies 21, 18 and 13 (Chitayat *et al,* 2011). Trisomy 18 (T18) is the second most common autosomal aneuploidy in newborns after trisomy 21 (Hook *et al,* 1983), with a prevalence of 1/3,000 births and trisomy 13 (T13) is the third most common cause of autosomal aneuploidy (Hook *et al,* 1983), with a prevalence of 1/5,000 births. In Brazil all women can have access to prenatal care, but there is no national policy for universal screening for aneuploidies, which may lead to late prenatal care and late diagnosis.

These severe and potentially lethal polymalformative syndromes are associated with a high rate of spontaneous abortion, intrauterine death, and short postnatal life with early neonatal death (Nicolaides, 2003), due to the presence of multiple anatomical abnormalities, including cardiovascular, neurological, renal, gastrointestinal, and skeletal malformations (Edwards et al., 1960; Patau et al, 1960; Springett et al., 2015). Currently, the reduced prevalence of these disorders in developed countries and the heterogeneity of the studies on diverse populations, leads to a lack of information about the follow-up of T13 and T18 pregnancies, their natural histories. and the overall outcomes after prenatal diagnosis. Another important point is the difference in legislation of termination of pregnancy for fetal conditions in countries where the studies were performed (So et al., 2017). In most of the countries, when a severe fetal malformation or chromosomal disorder is identified, the couple has the opportunity to decide for a medically induced abortion or therapeutic anticipation of delivery. The rates of termination of pregnancy may be above 78% for T13 and T18 (Lakovschek et al. 2011). The natural history of these trisomies is characterized by a high risk of spontaneous fetal loss, with pregnancy loss rates ranging from 49-66% for pregnancies with T13 and between 72-87% for T18 (Morris and Savva, 2008; Lakovschek et al., 2011; Houlihan and O'Donoghue, 2013). Less than 10% of the live births of T13 and T18 have a 1-year overall survival (Lin et al., 2006; Vendola et al., 2010; Houlihan and O'Donoghue, 2013). However, few studies describe isolated cases with greater survival, after performing a large number of interventions (e.g., orthopedic, neurological, cardiac) with poor outcomes and a very precarious quality of life (Redheendran et al., 1981, Petek et al., 2003, Vendola et al., 2010; Bruns and Campbell, 2014). The median survival rate for affected infants was 3 and 15 days for both trisomies (Brewer et al., 2002; Sibiude et al., 2011; Houlihan and O'Donoghue, 2013).

Brazilian legislation criminalizes abortion, and only contemplates interruption of

pregnancy in cases of risk of maternal death, fetuses diagnosed with anencephaly, and for cases of rape; in some specific cases a voluntary termination of pregnancy may be asked after judicial authorization. For most of cases with several and potentially lethal malformations, a routine follow-up of pregnancies is performed and the outcome of the natural history is expected.

This study aims to describe the natural history of T13 and T18 after prenatal diagnosis, in a country where the termination of pregnancy for these cases is not legally available, describing the characteristics of the fetuses, the course and final outcome of the gestation. This information should improve the processes of genetic counseling for pre- and postnatal follow-up. Knowledge of the possible outcomes and complications in these conditions may help parents and multidisciplinary teams to make decisions related to the future management of these pregnancies.

SUBJECTS AND METHODS

Subjects

This was a retrospective cohort study, approved by the ethics committee of the Hospital de Clínicas de Porto Alegre in March 2016. The sample size calculation was performed in the WinPEPI version 11.63, based on the study by Lakovoschek *et al.* (2011). Considering the proportion of prenatal diagnosis of T13 (assumed proportion: 0.25) with a sample power of 80% and an acceptable difference of 10%, the final sample size, 31 individuals would be required. Considering the proportion of prenatal diagnosis of T18 (assumed proportion: 0.11) with a sampling power of 80% and an acceptable difference of 10%, the final sample size required would be 17 individuals.

All cases with result of full T13 and full T18 were identified from the personal database of the researchers and the records of karyotype results performed by amniocentesis. The medical records of participants with prenatal diagnosis of T13 and T18 by amniocentesis were analyzed from October 1994 to October 2017, and we included those with complete information about the final outcome of pregnancy. When the medical records were incomplete, the participants were contacted by telephone, using a previously structured script in order to obtain the missing data.

DATA COLLECTION AND STATISTICAL ANALYSIS

Datacollected included demographic information (e.g., age, parity, comorbidities); gestation considerations (e.g., reason for referral to fetal medicine, complications); gestational age at diagnosis of trisomy, type of outcome (e.g., miscarriage, intrauterine

death, or live birth); maternal complications, maternal inpatient time, and ultrasound data (e,g., fetal sex detected malformations); gestational age at delivery, delivery route, and overall survival in days for the live births (Figure 1).

The data was collected using a semi structured questionnaire and then imported into SPSS® Statistics Version 18.0 (SPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc.). The normality of each variable was evaluated through the Shapiro-Wilk Test. Descriptive statistics were used to present the data. Continuous variables were summarized as medians and 95% confidence intervals (CI) and categorical variables summarized as absolute (n) and relative (n%) frequencies. The Chi-Square test with adjusted residual analysis was performed. Statistical significance was set at 5% for all analyses.

RESULTS

The local prevalence of T13 and T18 in the Hospital de Clinicas de Porto Alegre, over the last 23 years was 0.15/1,000 births and 0.34/1,000 births, respectively. We had 85,000 births and we performed 1,104 punctures for fetal karyotype. Sixty-five of them (5.8%) had a diagnosis of T13 or T18. Of these 65 exams, there were 20 cases (31%) of full T13 and 45 cases (69%) of full T18 (Figure 2).

CHARACTERISTICS OF PREGNANT WOMEN

Forty-eight cases had a diagnosis of trisomy during the time of the study. Six of them were excluded. Three had incomplete information and the researchers could not establish contact with them; and the other three performed a voluntary termination of pregnancy after judicial authorization. Forty-two participants were included in the study, 13 (31%) were diagnosed with T13 and 29 (69%) with T18. As shown in Table 1, 47.6% of the women were between 19 and 34 years old, while 45.2% were older than 35 years at the time of trisomic gestation. There was no statistical difference between T13 and T18 (χ^2 , p=0.142), but the proportion of women above 35 years was higher for T18 (n=16 of 29, 55.2%) when compared to T13 (n=3 of 11, 23.1%). The median (95% CI) age for T13 was 30 (26.15–35.39) years and 36 (30.85–36.94) years for T18.

Fourteen subjects (33.3%) were primiparous, and there was no statistical difference regarding parity between T13 and T18 (χ^2 test, p=1.000). None of the pregnant women had a history of having a previously conceived pregnancy with T13 or T18 diagnosis. Nineteen percent of the participants had some comorbidity at the time of gestation, but without statistical difference between the two trisomies (χ^2 test, p=0.384). The prevalence of diabetes mellitus was low in our series (Table 1).

FETAL CHARACTERISTICS AND DIAGNOSIS OF TRISOMY

Thirteen cases of T13 and 29 cases of T18 were identified, all of them having a prenatal diagnosis with full trisomy by karyotype. No cases of trisomy were identified in twin gestations. The fetal sex distribution did not differ between the two trisomy groups: 50% male and 50% female for both (χ^2 test, p=1.000). Even though the literature describes a ratio of 3:1 female to male fetuses for T18, this proportion was not evidenced in our series.

The gestational age at diagnosis was considered based on the gestational age when amniocentesis was performed. Three categories were defined: the first trimester until 13 weeks + 6 days. Second trimester was defined from 14 to 28 weeks and third trimester from 28 weeks + 1 day. One case (2.4%) was diagnosed in the first trimester, corresponding to the T18 group. Twenty-four cases (57.1%) were diagnosed in the second trimester and the other 17 cases (40.5%) in the third trimester. There was no difference between T13 and T18 gestational age at diagnosis (χ^2 test, p=0.728).

The most common reason for the referral of those women to a specialized follow-up of high risk-profile pregnancy was the finding of fetal malformations by ultrasound, corresponding to 92.9% (39/42) of the cases. The presence of altered nuchal translucency (a nuchal translucency higher than percentile 95) and the risk-profile of malformations were also considered for referral as shown in Table 2.

CONGENITAL DEFECTS

The structural abnormalities detected by ultrasonography or described by the pathologist during autopsy of the fetus with T13 and T18 diagnosis are displayed in Table 3. In total, 30 (71.4%) participants had a cardiac defect (e.g., interatrial communication, interventricular communication, and/or atrioventricular septal defect) detected by ultrasound (T13=53.5%, T18=79.3%). Gastrointestinal malformations were identified in 12 (28.6%) subjects (T13=23.1%, T18=31.9%). Genitourinary malformations were identified in 20 (47.6%) cases (T13=61.5%, T18=41.4%). Malformations of the central nervous system were identified in 27 (64%) participants (T13=84.6%, T18=55.2%). Abnormalities of limbs were present in 46.2% of cases of T13 and 65.5% of T18.

The most common malformations found in fetuses with T13 were: holoprosencephaly (n=8, 61.5%), cleft lip and/or palate (n=7, 53.8%), renal morphology changes (including cystic kidneys, dysplastic kidneys, enlarged, hyperechogenic, and other non-specific kidney alterations) present in 6 (46.2%) cases, and ventricular septal defect (n=5, 38.5%). The most common morphological

changes in T18 were: ventricular septal defect (n=15, 51.7%), hand defects (n=15, 51.7%), and clubfoot (n=10, 34.5%).

There was an increased incidence of cleft lip and/or palate (χ^2 test, p=0.008), pyelocalyceal dilatation (χ^2 test, p=0.037) and holoprosencephaly (χ^2 test, p<0.0001) on T13 cases, corroborating data reported in the literature. The finding of short bones was exclusive of T18, corresponding to 6 (14.3%) cases.

PREGNANCY OUTCOME AND SURVIVAL

The outcome of pregnancies with T13 and T18 is shown in Table 4. Gestational age at delivery was categorized into four groups, based on clinical relevance. Miscarriage was considered when the end of gestation occurred before 22 weeks + 6 days, because this is the limit gestational age of viability established in the Hospital de Clínicas of Porto Alegre; extremely preterm, those gestations that ended between 23 weeks and 31 weeks + 6 days; preterm, those whose end of gestation occurred between 32 weeks and 36 weeks + 6 days and at term, those pregnancies that reached 37 weeks or more.

The miscarriage rate for T18 was 9% (3/29) while there were no cases in T13. The fetal death rate was 46.2% (4/13) for T13 and 51.7% (15/29) for T18. The rate of live births was 54% (7/13) for T13; there was one extremely preterm birth (before 32 weeks), 57% (4/7) preterm births between 32 and 36 weeks + 6 days and 2 cases (28%) were at term pregnancies. The median (95% CI) survival of these infants was one day (33.55–90.40). Live births: 71% (5/7) died within the first 24 hours. There were two cases that exceeded the first week of life, one with 14 days and the other with 180 days.

For T18 the rate of live births was 37.9% (11/29), and 17% (2/11) of the cases were born extremely preterm, 56% (6/11) were preterm between 32 and 36 weeks + 6 days and 27% (3/11) of the cases were at term pregnancies. The median (95%CI) survival of these neonates was 2 days (-1.89–13.17). Five cases (45%) died within the first 24 hours and 45% (5/11) died in the first week of life. One case (10%) exceeded the first month of life, with a survival of 39 days. No case for both trisomies reached the first year of life.

When analyzed on a case-by-case basis, it was observed that fetuses with greater survival were those in which neonatal investment was performed. They underwent multiple exams and procedures, including mechanical ventilation, surgical correction of some defects to guarantee vital functions, as feeding, breathing among others. Generally, their parents had a late diagnosis of trisomy, less time of prenatal care, and probably less time to prepare for mourning. Those couples with earlier

diagnosis, with a better follow-up and counseling during the prenatal care, have opted for just a support or palliative management at birth for the newborn (Figure 3).

GESTATION AT DELIVERY AND COMPLICATIONS

Only 7.1% (3/42) of the total trisomies were miscarriages, and there were no cases within the T13 group, probably due to late diagnosis of pregnancy and a late prenatal referral.

Extremely preterm were 23.8% (10/42) of the cases, being 15.4% (2/13) for T13 and 27.6% (8/29) for T18. There were 54.8% (23/42) of premature cases, 69.2% (9/13) for T13 and 48.3% (14/29) for T18. Full-term gestation occurred in 14.3% (6/42) of the cases, with 15.4% (2/13) for T13 and 13.8% (4/29) for T18. When considering both trisomies, there was no difference between the gestational ages at the delivery (χ^2 test, p=0.450).

The delivery route was analyzed for both groups, observing that 69% (29/42) of the births were vaginal delivered, occurring in 69.2% (9/13) of the T13 and in 69% (20/29) of the T18. Cesarean section (CS) was performed in 31% (13/42) of the trisomy cases, with 30.8% (4/13) for T13 and 31% (9/29) for T18. Some of the indications for CS were obstetric causes (e.g., abnormal fetal presentation, cesarean iterativity, and maternal contraindication for vaginal delivery). Despite prenatal counseling about fetal diagnosis, in few cases of non-reassuring fetal condition and parent's desire to invest in the newborn, CS was also performed. There was no difference in the delivery route for the two trisomies (χ^2 test, p=1.000).

Considering complications associated with pregnancy and birth, 21.4% (9/42) of the participants presented some intercurrence. Gestational hypertension disorders (e.g., gestational hypertension, pre-eclampsia, and pre-eclampsia superimposed on chronic hypertension) were the most observed, present in 11.9% (5/42) of the cases of trisomy. Prevalence of hypertensive disorders was 30.8% (4/13) in T13 cases and 3.4% (1/29) in T18, but with a marginal statistical difference (χ^2 test, p=0.054).

Furthermore, when evaluating the length of maternal hospitalization stay after the final outcome of a trisomic gestation, 14.3% (5/42) had a maternal inpatient time of more than 3 days, and most of these cases occurred in mothers whose outcome of gestation was live birth. However, there was no statistical difference between the two trisomies (χ^2 test, p=0.892).

DISCUSSION

This study describes the cases of T13 and T18 diagnosed in the past 23 years, at the Hospital de Clínicas in Porto Alegre, Porto Alegre/Brazil. Our cohort is one of

the largest described so far in the literature that followed the natural history of these trisomies after prenatal diagnosis. All 42 of the included participants had prenatal diagnosis of full trisomy performed by amniocentesis for fetal karyotype.

Brazil is a country with a low resources health system (Monteklo and Aquino, 2011). This scenario is reflected in the quality of the pre-conception assessment and follow-up of pregnant women, mainly characterized by delay in the diagnosis of pregnancy, the late start of prenatal control, and inadequate availability of obstetric ultrasound equipment. An example of this is the absence of a universal and structured prenatal screening program for risk assessment of fetal aneuploidy. Our results show that pregnant women started the prenatal control mainly after 16 weeks of gestational age, making the first trimester screening for Down Syndrome and other aneuploidies not feasible.

Up to 70% of aneuploidy cases can be detected with combined ultrasound morphological markers (e.g., nuchal translucency and maternal risk factors) (Nicolaides, 2003), even in the absence of more complex methods that require greater resources, such as the use of biochemical markers, or complex ultrasound evaluations. Actions in order to increase availability of screening earlier in pregnancy have to be taken.

The main reason for the referral to the hospital was the presence of malformations detected by ultrasound, corresponding to 92.9% of the cases. The number and certain specific fetal malformations are directly associated with an increased risk-profile for aneuploidies; so obstetric sonographers need to know the pattern of malformations associated with each chromosomal anomaly (Nicolaides *et al.*, 1992). In our cases, it was possible to correlate some malformations and findings to each specific trisomy, thus increasing the diagnostic suspicion when detected in the ultrasound examination (Kroes *et al.*, 2014). This made it possible to correlate cleft lip and/or palate, holoprosencephaly and pyelocalyceal dilations with T13, which is consistent with data described in the literature (Patau *et al.*, 1960).

Among the 13 cases of T13 (47,+13) and 29 cases of T18 (47,+18) identified between October 1994 and October 2017, there was a difference regarding maternal age. In the T18 group most of women were over 35 years, similar to what is described in the literature (Chitayat *et al.*, 2011), and there was no statically significant between the two trisomies in our study. When parity was considered, also no difference was found between primiparous and multiparous mothers.

When analyzing the natural history and the outcomes of these pregnancies, we observed approximately 50% of intrauterine fetal deaths for T13 and T18, and a short overall survival at birth for both conditions (above 50% death in the first 24 hours for live births). Thus, we confirm the potentially lethal condition of these polymalformative syndromes (Irving et al 2011, Lakovschek *et al.*, 2011; Houlihan

and O'Donoghue, 2013).

One important finding is the high rate of cesarean section performed for T13 and T18 fetuses, including among primiparous women. This means that the counseling process offered to the parents should continue to be improved. The increased risk of emergency cesarean section compared to other types of delivery is well documented in the literature, as well as the potential implications of having an emergency cesarean section in future pregnancies (Villar *et al.*, 2006).

We observed that women who started late the prenatal control and with a late diagnosis of the aneuploidy had a higher incidence of cesarean delivery and more frequently chose to invest in the newborn. This cannot be affirmed without comparing C-section prevalence in Brazil and/or in similar settings, but this could be explained because these parents had less time for multidisciplinary team counseling, more difficulties to understand the fetal condition, and less time to elaborate mourning. The aim of counseling is always to provide complete information to the parents helping them in the decision-making process and respecting their autonomy. When the parents' desire is to invest in the polymalformed newborn, the medical team offers an appropriate care based on the natural history of each condition. In this way, women who had a late diagnosis more frequently decided not to perform fetal necropsy and considered this pregnancy as a limitation to re-conceive.

Considering the newborns, greater survival was related to the number of procedures and interventions performed, but these did not enable them to reach the first year of life.

An important point for newborns with diagnosis of T13 or T18 is the management and care offered to them. Parents and health professionals must decide between support or palliative care without invasive procedures, or total investment. This is especially important in countries where the termination of pregnancy is not legal, or when parents decide to continue with the pregnancy. This decision has an impact not only for the newborn and the mother, but also reflects in costs for the health system. In a study done in the United Kingdom, it was estimated that children with malformations who underwent multiple surgeries, examinations, and procedures to survive 180 days could represent a daily hospitalization cost of approximately 1000 US dollars (Shetty *et al.*, 2016), depending on the type of procedure performed. However, despite such procedures, the natural history of the disease was not modified, because the interventions are not curative and only improve the quality of life.

The international guidelines for resuscitation and management of neonates with malformations (Wyckoff *et al., 2015*) recommend providing specific palliative or supportive care, and always stressing that decisions must be taken together with the medical team, respecting the autonomy of the parents (Lin *et al., 2006*;

Nelson *et al.*, 2012; Shetty *et al.*, 2016). A positive impact in terms of public health and economic cost will be greater if some strategies were developed, such as the creation of structured evidence based-protocols considering the palliative and support strategies for newborns with aneuploidies.

Our results could support the reassessment of collective health policies and initiate the discussion about pregnancy termination for lethal polymalformative syndromes in a country where this kind of action is not legally approved. This is important from a public health perspective, as the termination of pregnancy could result in a positive impact on maternal morbidity/mortality and, secondarily, on the costs for the health system (Parmar *et al.*, 2015).

During the years in which the study was conducted, two types of decisions were taken. Some parents expressed their desire of pregnancy termination after diagnosis for T13 or T18. This request was made with judicial authorization for those cases of trisomy with severe and lethal malformations. On the other hand, many couples chose the option to continue with the pregnancy after diagnosis of an aneuploidy (Sibiude *et al.*, 2011; So *et al.*, 2017). Therefore, we emphasize the importance of structured protocols and trained multidisciplinary teams who perform an early diagnosis, an appropriate counseling process, and a quality follow-up to support the decision-making process.

This information regarding the natural history of pregnancies with prenatal diagnosis of T13 and T18 has local and international relevance, since it is associated with previous related studies and could improve the quantity and quality of information available for the counseling and follow-up processes. Local and international protocols or guidelines could be made to orientate the management of these pregnancies during the gestation period, delivery, and postpartum, considering both mother and newborn.

From the prenatal diagnosis of a fetus with T13 or T18, adequate clinical follow-up can be given to the parents and they can prepare for the probable outcome. An unexpected postnatal diagnosis can be extremely traumatic, as the parents may have little time to adjust to the reality of a child with significant malformations and the high risk of neonatal death. On the other hand, the parents could be assisted to take an informed decision-making process and thus determine together with a multidisciplinary team whether to maintain the pregnancy or requests its termination.

One limitation of our study is that the information contained in medical records is often incomplete or confusing. In addition, a recall bias could be present when it was necessary to establish telephone contact with the participants in order to get the information.

The main strength of the present study is associated with the diagnosis and inclusion criteria of the participants. All of the cases had prenatal diagnosis with

full trisomy after amniocentesis for fetal karyotype. Cell culture was carried out by a biologist with experience in cytogenetics, and the follow-up and counseling were provided by the same multidisciplinary team formed by specialists in fetal medicine, experienced sonographers, clinical geneticists, psychologists, neonatologists, pediatricians, and complemented by the opinion of experts in pediatric surgery and pediatric urology. This allowed a homogeneous follow-up and management for these cases during those 20 years in which the study was performed. Notably, considering the worldwide prevalence and previous studies for T13 and T18 pregnancies, we have one of the largest series of cases.

CONCLUSIONS

The results of this study confirm the bad prognosis for fetuses with trisomy 13 or 18. More than 50% of intrauterine death occurred and, among live births, a short postnatal life was observed with a median survival time of one day for T13 and two days for T18. For both trisomies, no patient reached the first year of life. For those who had a longer survival, multiple invasive and expensive procedures were required without success in prolonging life beyond 180 days.

The results of this study are consistent with those referenced in the literature, emphasizing the need of structured protocols and guidelines aiming at early T13 and T18 diagnosis, prenatal care, gestation/parents follow-up, and counseling processes. For those couples with earlier diagnosis, a better follow-up and counseling during the prenatal care lead to the option for a support or palliative management of the newborn.

Current and local data about the natural history of T13 and T18 are necessary. Also, this data can contribute to include new therapeutic options in the actual legislation. Finally, when the counseling process is appropriate, it becomes easier to take decisions respecting the parent's autonomy and to look for better outcomes for both, the mother and the fetus.

ACKNOWLEDGMENTS

We would like to thank all of our patients, who are the reason and the goal of all our actions. Special thanks to the Fetal Medicine Group of the Hospital de Clinicas de Porto Alegre for their contribution and constant support.

CONFLICT OF INTEREST

The authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

AUTHOR CONTRIBUTIONS

Study conception and design: Magalhães, J.A and Duque, J.A

Acquisition of data: Duque, J.A and Zachia, S.de A

Analysis and interpretation of data: Duque, J.A and Ferreira, Ch. F

Drafting of Manuscript: Duque, J.A and Sanseverino, M.T and Gus, R.

Critical Revision: Duque, J.A and Magalhães, J.A, Sanseverino, M.T, and Gus,

R.

All authors read and approved the submitted version of the manuscript.

REFERENCES

Brewer CM, Holloway SH, Stone DH, Carothers AD and FitzPatrick DR (2002) Survival in trisomy 13 and trisomy 18 cases ascertained from population based registers. J Med Genet 39:e54.

Bruns D and Campbell E (2014) Twenty two survivors over the age of 1 year with full trisomy 18: Presenting and current medical conditions. Am J Med Genet A 164:610-619.

Chitayat D, Langlois S, Wilson RD, Audibert F, Blight C, Brock JA and Johnson JA (2011) Prenatal screening for fetal aneuploidy in singleton pregnancies. J Obster Gynaecol Canada 33:736-750.

Edwards JH, Harnden DG, Cameron AH, Crosse VM and Wolf OH (1960) A new trisomic syndrome. Lancet 275:787-790.

Holmgren C and Lacoursiere DY (2008) The use of prenatal ultrasound for the detection of fetal aneuploidy. Clin Obstetr Gynecol 51:48-61.

Hook EB, Cross PK and Schreinemachers DM (1983) Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA 249:2034-2038.

Houlihan OA and O'Donoghue K (2013) The natural history of pregnancies with a diagnosis of trisomy 18 or trisomy 13; A retrospective case series. BMC Pregnancy Childbirth 13:209.

Irving C, Richmond S, Wren C, Longster C and Embleton ND (2011) Changes in fetal prevalence and outcome for trisomies 13 and 18: A population-based study over 23 years. J Mater Fetal Neonatal Med 24:137-141.

Kroes I, Janssens S and Defoort P (2014) Ultrasound features in trisomy 13 (Patau syndrome) and trisomy 18 (Edwards syndrome) in a consecutive series of 47 cases. Facts Views Visi ObGyn 6:245.

Lakovschek IC, Streubel B and Ulm B (2011) Natural outcome of trisomy 13, trisomy 18, and triploidy after prenatal diagnosis. Am J Med Genet A 155:2626-2633.

Lin HY, Lin SP, Chen YJ, Hung HY, Kao HA, Hsu CH, Chen MR, Chang JH, Ho CS *et al.* (2006) Clinical characteristics and survival of trisomy 18 in a medical center in Taipei, 1988–2004. Am J Med Genet A 140:945-951.

Monteklo VB and Aguino R (2011) The health system of Brazil, Salud Públ México 53:120-131.

Morris JK and Savva GM (2008) The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet A 146:827-832.

Nelson KE, Hexem KR and Feudtner C (2012) Inpatient hospital care of children with trisomy 13 and trisomy 18 in the United States. Pediatrics 129:869-876.

Nicolaides KH (2003) Screening for chromosomal defects. Ultrasound Obstetr Gynecol 21:313-321.

Nicolaides KH, Snijders RJM, Campbell S, Gosden CM and Berry C (1992) Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet 340:704-707.

Pandya PP, Snijders RJ, Johnson SP, Lourdes Brizot M and Nicolaids KH (1995) Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynecol 102:957-962.

Parmar D, Leone T, Coast E, Murray SF, Hukin E and Vwalika B (2015) Cost of abortions in Zambia: A comparison of safe abortion and post abortion care. Global Publ Health 12:236-249.

Patau K, Smith D, Therman E, Inhorn S and Wagner H (1960) Multiple congenital anomaly caused by an extra autosome. Lancet 275:790-793.

Petek E, Pertl B, Tschernigg M, Bauer M, Mayr J, Wagner K and Kroisel PM (2003) Characterisation of a 19-year-old" long-term survivor" with Edwards syndrome. Genetic Counsel 14:239-244.

Redheendran R, Neu RL, Bannerman RM and Opitz JM (1981) Long survival in Trisomy-13-syndrome: 21 cases including prolonged survival in two patients 11 and 19 years old. Am J Med Genet A 8:167-172.

Shetty S, Kennea N, Desai P, Giuliani S and Richards J (2016) Length of stay and cost analysis of neonates undergoing surgery at a tertiary neonatal unit in England. Ann R Coll Surg Engl 98:56-60.

Sibiude J, Gavard L, Floch-Tudal and Mandelbrot L (2011) Perinatal care and outcome of fetuses with trisomies 13 and 18 following a parental decision not to terminate the pregnancy. Fetal Diagn Ther 29:233-237.

So PL, Cheng KYY, Cheuk KY, Chiu WK, Mak SL, Mok SL, Lo TK, Yung WK, Lo FM, Chung HYB *et al.* (2017) Parental decisions following prenatal diagnosis of sex chromosome aneuploidy in Hong Kong. J Obstetr Gynaecol Res 43:1821-1829.


Springett A, Wellesley D, Greenlees R, Loane M, Addor MC, Arriola L,Bergman J, Cavero-Carbonell C, Csaky-Szunyogh M, Draper ES *et al.* (2015) Congenital anomalies associated with trisomy 18 or trisomy 13: A registry-based study in 16 European countries, 2000–2011. Am J Med Genet A 167:3062-3069.

Vendola C, Canfield M, Daiger SP, Gambello M, Hashmi SS, King T, Noblin SJ, Waller DK, Hecht JT (2010) Survival of Texas infants born with trisomies 21, 18, and 13. Am J Med Genet A 152:360-366.

Villar J, Valladores E, Wojdyla D, Zavaleta N, Carroli G, Velazco A, Shah A, Campodónico L, Bataglia V, Fagundes A *et al.* (2006) Caesarean delivery rates and pregnancy outcomes: The 2005 WHO global survey on maternal and perinatal health in Latin America. Lancet 367:1819-1829

Wyckoff MH, Aziz K, Escobedo MB, Kapadia VS, Kattwinkel J, Perlman JM (2015) Neonatal resuscitation. Circulation 132(suppl 2):S543-S560.

FIGURE LEGENDS



*T13: Trisomy 13, T18: Trisomy 18, HCPA: Hospital de Clínicas de Porto Alegre.

Figure 1 – Flowchart of patients diagnosed with trisomy 13 or trisomy 18.




Figure 2 – Number of punctures vs. diagnoses of trisomy 13 or trisomy 18 during 23 years.




Figure 3 – Offspring death distribution.

Variables – n(n%)	Total <i>N</i> =42	T 13 n=13	T18 n=29	*p-value
Maternal age				
≤18 years	3(7.1)	1(7.7)	2(6.9)	0.142
19-34 years	20(47.6)	9(69.2)	11(37.9)	0.142
≥35 years	19(45.2)	3(23.1)	16(55.2)	
Parity				
First pregnancy	14(33.3)	4(30.8)	10(34.5)	1.000
Multiparous	28(66.7)	9(69.2)	19(65.5)	
Gestational age at diagnosis	. (0. 1)	2(2.2)	. (0. 1)	
1°trimester	1(2.4)	0(0.0)	1(3.4)	
2° trimester	24(57.1)	7(53.8)	17(58.6)	0.728
3° trimester	17(40.5)	6(46.2)	11(37.9)	
Comorbidities				
Yes	8(19.0)	4(30.8)	4(13.8)	0.384
No No	34(81.0)	9(69.2)	4(13.6) 25(86.2)	0.564
	J4(01.0)	<i>3</i> (03.2)	23(00.2)	
Fetus Sex	04/50.03	7/50.0	4444000	4.000
Male	21(50.0)	7(53.8)	14(48.3)	1.000
Female	21(50.0)	6(46.2)	15(51.7)	
Gestational age at delivery				
<22+6 weeks	3(7.1)	0(0.0)	3(10.3)	
23 – 31+6 weeks	10(23.8)	2(15.4)	8(27.6)	0.450
32 – 36+6 weeks	23(54.8)	9(69.2)	14(48.3)	
>37 weeks	6(14.3)	2(15.4)	4(13.8)	
M				
Maternal Complications	0/01 4\	4(20.0)	E(17.0)	0.501
Yes	9(21.4)	4(30.8)	5(17.2)	0.561
No	33(78.6)	9(69.2)	24(82.8)	
Type of Maternal Complications				
None	33(78.6)	9(69.2)	24(82.8)	
Gestational Hypertensive Disorders**	5(11.9)	4(30.8)	1(3.4)	0.054
Gestational Diabetes	3(7.1)	0(0.0)	3(10.3)	0.001
Others***	1(2.4)	0(0.0)	1(3.4)	
Maternal hospital stay beyond 3 days	0/// 5			
Yes	6(14.3)	2(15.4)	4(13.8)	0.892
No	36(85.7)	11(84.6)	25(86.2)	

Table 1 - Sample characterization of trisomy 13 and 18 pregnancies.

Legend: n: absolute frequency; n%: relative frequency; p: statistical significance; **gestational hypertensive disorders involve gestational hypertension, pre-eclampsia, and pre-eclampsia superimposed on chronic hypertension; **other complications involve depression, hypothyroidism, and asthma; T13: trisomy 13; T18: trisomy 18; *Chi-Square test with adjusted residual analysis. Statistical significance was set as p≤0.05 for all analyses.

Variables – n(n%)	Total <i>N</i> =42	T13 <i>n</i> =13	T18 n=29	*p-value
Abnormal NT **				
Yes	9(21.4)	1(7.7)	8(27.6)	0.296
No	33(78.6)	12(92.3)	21(72.4)	
Malformations in routine ultrasound				
Yes	39(92.9)	12(92.3)	27(93.1)	1.000
No	3(7.1)	1(7.7)	2(6.9)	
High maternal risk-profile***	4.4(00.0)	F(00 F)	0(04.0)	
Yes	14(33.3)	5(38.5)	9(31.0)	0.906
No	28(66.7)	8(61.5)	20(69.0)	2.230

Table 2 - Referral reasons for specialized follow-up of high risk-profile pregnancies.

Legend: n: absolute frequency; n%: relative frequency; p: statistical significance; **nucal translucency is abnormal when higher than 95 percentile for gestational age; *** high maternal risk-profile is given by age, personal history of the fetus with malformations, and/or personal history of genetic disorders. T13: trisomy 13; T18: trisomy 18; NT: nucal translucency. *Chisquare test with adjusted residual analysis. Statistical significance set as $p \le 0.05$ for all analyses.

Variables – n(n%)	Total <i>N</i> =42	T13 <i>n</i> =13	T18 <i>n</i> =29	*p-value
Cardiac				
Yes	30(71.4)	7(53.8)	23(79.3)	0.187
No	12(28.6)	6(46.2)	6(20.7)	
IAC				
Yes	13(31.0)	4(30.8)	9(31.0)	1.000
No	29(69.0)	9(69.2)	20(69.0)	
IVC				
Yes	20(47.6)	5(38.5)	15(51.7)	0.514
No	20(52.4)	8(61.5)	14(48.3)	
AVSD				
Yes	10(23.8)	2(15.4)	8(27.6)	0.391
No	32(76.2)	11(84.6)	21(72.4)	
Gastrointestinal				
Yes	12(28.6)	3(23.1)	9(31.0)	0.874
No	30(71.4)	10(76.9)	20(69.0)	
Omphalocele				
Yes	11(26.2)	3(23.1)	8(27.6)	1.000
No	31(73.8)	10(76.9)	21(72.4)	
Gastroschisis				
Yes	0(0.0)	0(0.0)	0(0.0)	1.000
No	42(100.0)	13(100.0)	29(100.0)	
Duodenal atresia				
Yes	0(0.0)	0(0.0)	0(0.0)	1.000
No	42(100.0)	13(100.0)	29(100.0)	
Esophageal Atresia				
Yes	2(4.8)	0(0.0)	2(6.9)	0.852
No	40(95.2)	13(100.0)	27(93.1)	
Genitourinary				
Yes	20(47.6)	8(61.5)	12(41.4)	0.320
No	22(52.4)	5(38.5)	17(58.6)	

Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 8 Renal morphology changes *** 12(28.6) 6(46.2) 6(20.7) 0.187 No 30(71.4) 7(53.8) 23(79.3) 0.037 Pyelocalyceal dilatation 7(16.7) 5(38.5) 2(6.9) 0.037 No 35(83.3) 8(61.5) 27(93.1) 0.037 Central Nervous System Yes 27(64.3) 11(84.6) 16(55.2) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.481 Ventriculomegaly Yes 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 1400 140.4 140.4 140.4 140.4 140.4 140.4 140.5 140.4 140.4 140.5 140.4 140.4 140.5 140.4 140.4 140.4 140.4 140.4<	Single umbilical artery				
Renal morphology changes ** Yes 12(28.6) 6(46.2) 6(20.7) 0.187 No 30(71.4) 7(53.8) 23(79.3) PP Pyelocalyceal dilatation 7(16.7) 5(38.5) 2(6.9) 0.037 No 35(83.3) 8(61.5) 27(93.1) 0.136 Central Nervous System Yes 27(64.3) 11(84.6) 16(55.2) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.481 0.481 No 15(35.7) 2(15.4) 13(44.8) 0.481 No 29(90.0) 8(61.5) 21(72.4) 0.481 Holoprosencephaly Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) 0.001 Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9)		'	, ,	, ,	0.816
Yes 12(28.6) 6(46.2) 6(20.7) 0.187 No 30(71.4) 7(53.8) 23(79.3) 0.187 Pyelocalyceal dilatation 7(16.7) 5(38.5) 2(6.9) 0.037 No 35(83.3) 8(61.5) 27(93.1) 0.037 Central Nervous System 27(64.3) 11(84.6) 16(55.2) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.481 Ventriculomegaly Yes 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 0.481 Holoprosencephaly Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.326 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1)<		33(78.6)	11(84.6)	22(75.9)	
No 30(71.4) 7(53.8) 23(79.3) Pyelocalyceal dilatation 7(16.7) 5(38.5) 2(6.9) 0.037 No 35(83.3) 8(61.5) 27(93.1) 0.037 Central Nervous System 7(24.3) 11(84.6) 16(55.2) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.481 Ventriculomegaly Yes 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 0.481 No 29(69.0) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) ≤0.0001 Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.326 Agenesis of corpus callosum Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 37(88.1) 10(76.9) 27(93.1) 0.326 No 37(88.1) 10(76.9) 19(65.5) <td></td> <td>10/00 ()</td> <td>C(4C O)</td> <td>C(00.7)</td> <td>0.407</td>		10/00 ()	C(4C O)	C(00.7)	0.407
Pyelocalyceal dilatation Yes 7(16.7) 5(38.5) 2(6.9) 0.037 No 35(83.3) 8(61.5) 27(93.1) 0.037 Central Nervous System Yes 27(64.3) 11(84.6) 16(55.2) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.481 Ventriculomegaly Yes 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 1.000 1.000 Holoprosencephaly Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) 0.0001 0.0001 No 33(78.6) 11(84.6) 22(75.9) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.400 No		, ,	, ,	` '	0.187
Yes 7(16.7) 5(38.5) 2(6.9) 0.037 No 35(83.3) 8(61.5) 27(93.1) 0.037 Central Nervous System 7(64.3) 11(84.6) 16(55.2) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.136 Ventriculomegaly Yes 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 0.481 Holoprosencephaly Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) 0.001 Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 1.000 Limbs abnormalities Yes 6(14.3) 0(0.0) <td></td> <td>30(71.4)</td> <td>7 (55.6)</td> <td>20(79.0)</td> <td></td>		30(71.4)	7 (55.6)	20(79.0)	
No 35(83.3) 8(61.5) 27(93.1) Central Nervous System 27(64.3) 11(84.6) 16(55.2) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.481 Ventriculomegaly Ves 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 0.481 Holoprosencephaly Yes 9(21.4) 8(61.5) 21(72.4) 0.481 No 33(78.6) 5(38.5) 28(96.6) 0.0001 Myelomeningocele Ves 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.00 Limbs abnormalities Yes 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.195 No 36(85.7)	•	7(16.7)	5(38.5)	2(6.9)	0.037
Yes 27(64.3) 11(84.6) 16(55.2) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.136 Ventriculomegaly 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 0.481 Holoprosencephaly 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) 5 Myelomeningocele 9(21.4) 2(15.4) 7(24.1) 0.816 Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.400 Limbs abnormalities 25(59.5) 6(46.2) 19(65.5) 0.400 Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.195		, ,	• •		0.00.
Yes 27(64.3) 11(84.6) 16(55.2) 0.136 No 15(35.7) 2(15.4) 13(44.8) 0.136 Ventriculomegaly 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 0.481 Holoprosencephaly 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) 5 Myelomeningocele 9(21.4) 2(15.4) 7(24.1) 0.816 Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.400 Limbs abnormalities 25(59.5) 6(46.2) 19(65.5) 0.400 Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.195	Central Nervous System			, ,	
Ventriculomegaly Yes 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 0.481 Holoprosencephaly Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) 5(38.5) 28(96.6) Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 1.10 Limbs abnormalities Yes 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 No 36(85.7) 13(100.0) 23(79.3) 0.195 Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) <td>-</td> <td>27(64.3)</td> <td>11(84.6)</td> <td>16(55.2)</td> <td>0.136</td>	-	27(64.3)	11(84.6)	16(55.2)	0.136
Yes 13(31.0) 5(38.5) 8(27.6) 0.481 No 29(69.0) 8(61.5) 21(72.4) 0.481 Holoprosencephaly Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) 50.0001 Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 10.20 27(93.1) 10.20 Limbs abnormalities Yes 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 No 36(85.7) 13(100.0) 23(79.3) 0.195 Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 Yes 13(31.0) 3(23.1) 10(34.5) 0.705 Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7)	No	15(35.7)	2(15.4)	13(44.8)	
No 29(69.0) 8(61.5) 21(72.4) Holoprosencephaly Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) Limbs abnormalities Yes 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008					
Holoprosencephaly Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.326 Limbs abnormalities Yes 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.705 Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) 0.705 Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.644			, ,	` '	0.481
Yes 9(21.4) 8(61.5) 1(3.4) ≤0.0001 No 33(78.6) 5(38.5) 28(96.6) Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.326 Limbs abnormalities Yes 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.705 Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) 0.705 Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.644 No 22(52.4) <td></td> <td>29(69.0)</td> <td>8(61.5)</td> <td>21(72.4)</td> <td></td>		29(69.0)	8(61.5)	21(72.4)	
No 33(78.6) 5(38.5) 28(96.6) Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) 0.816 Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 0.400 Limbs abnormalities Yes 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.195 Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) 0.705 Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.644 Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000		0/21 4)	0/61 E)	1/2 4\	-0.0001
Myelomeningocele Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) Agenesis of corpus callosum 7(8.1) 11(84.6) 22(75.9) Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) Limbs abnormalities 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.195 Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.705 Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) 0.644 No 22(52.4) 8(61.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.004 <		'			≥0.0001
Yes 9(21.4) 2(15.4) 7(24.1) 0.816 No 33(78.6) 11(84.6) 22(75.9) Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 10.326 Limbs abnormalities 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.195 Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.195 Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) 196.5.5 Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.644 No 22(52.4) 8(61.5) 14(48.3)<		00(70.0)	3(33.3)	25(55.5)	
No 33(78.6) 11(84.6) 22(75.9) Agenesis of corpus callosum Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) 10 Limbs abnormalities 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.195 Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.644 No 22(52.4) 8(61.5) 14(48.3) 1.000 No 35(83.3) 11(84.6) 24(82.8) 1.000 Cleft / palate lip Yes 10(23.8) 7(5	<u> </u>	9(21.4)	2(15.4)	7(24.1)	0.816
Yes 5(11.9) 3(23.1) 2(6.9) 0.326 No 37(88.1) 10(76.9) 27(93.1) Limbs abnormalities 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) 0.400 Short bones 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.705 Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.644 Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) 0.008 Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		'	` '	` '	
No 37(88.1) 10(76.9) 27(93.1) Limbs abnormalities Yes 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008	Agenesis of corpus callosum				
Limbs abnormalities 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) Short bones 7(53.8) 10(34.5) 0.195 No 36(85.7) 13(100.0) 23(79.3) 0.195 Clubfoot 7(100.0) 23(79.3) 0.705 0.705 No 29(69.0) 10(76.9) 19(65.5) 0.705 Hands abnormalities 7(8.7) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.644 Diaphragmatic hernia 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip 7(53.8) 3(10.3) 0.008		• •	, ,	, ,	0.326
Yes 25(59.5) 6(46.2) 19(65.5) 0.400 No 17(40.5) 7(53.8) 10(34.5) Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		37(88.1)	10(76.9)	27(93.1)	
No 17(40.5) 7(53.8) 10(34.5) Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		0=(=0 =)	0(40.0)		
Short bones Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		` '		` '	0.400
Yes 6(14.3) 0(0.0) 6(20.7) 0.195 No 36(85.7) 13(100.0) 23(79.3) Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.644 Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		17 (40.5)	7 (55.6)	10(34.3)	
No 36(85.7) 13(100.0) 23(79.3) Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		6(14.3)	0(0 0)	6(20.7)	0 195
Clubfoot Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		• •	` '	` '	0.100
Yes 13(31.0) 3(23.1) 10(34.5) 0.705 No 29(69.0) 10(76.9) 19(65.5) Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) 0.644 Piaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008	Clubfoot	, ,	, ,	, ,	
Hands abnormalities Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		13(31.0)	3(23.1)	10(34.5)	0.705
Yes 20(47.6) 5(38.5) 15(51.7) 0.644 No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008	No	29(69.0)	10(76.9)	19(65.5)	
No 22(52.4) 8(61.5) 14(48.3) Diaphragmatic hernia 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip 7(53.8) 3(10.3) 0.008					
Diaphragmatic hernia Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		, ,	, ,	, ,	0.644
Yes 7(16.7) 2(15.4) 5(17.2) 1.000 No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		22(52.4)	8(61.5)	14(48.3)	
No 35(83.3) 11(84.6) 24(82.8) Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008	. •	7(16.7)	2(15.4)	5(17.2)	1 000
Cleft / palate lip Yes 10(23.8) 7(53.8) 3(10.3) 0.008		` '	, ,	, ,	1.000
Yes 10(23.8) 7(53.8) 3(10.3) 0.008		33(33.3)	. 1(0 1.0)	_ !(02.0)	
		10(23.8)	7(53.8)	3(10.3)	0.008
No 32(76.2) 6(46.2) 26(89.7)	No	32(76.2)	6(46.2)	26(89.7)	-

Table 3 - Structural abnormalities for trisomy 13 and trisomy 18.

Legend: n: absolute frequency; n%: relative frequency; p: statistical significance; **renal morphology changes involve cases of polycystic kidneys, renal dysplasias, and non specific renal changes; T13: trisomy 13; T18: trisomy 18; IAC: Inter Auricular Communication; IVC: Interventricular Communication; AVSD: Atrial Ventricular Septum Defect. *Chi-square test with adjusted residual analysis. Frequencies in bold: association between variables by Chi-square test with adjusted residual analysis. Statistical significance was set as p≤0.05 for all analyses.

Variable- n(n%)	Total <i>N</i> =42	T13 <i>n</i> =13	T18 <i>n</i> =29	*p-value
Miscarriage**				
Yes	3(7.1)	0(0.0)	3(10.3)	0.579
No	39(92.9)	13(100.0)	26(89.7)	

Intra-uterine death				
Yes	39(92.9)	6(46.2)	15(51.7)	1.000
No	3(7.1)	7(53.8)	14(48.3)	
Live birth				
Yes	14(33.3)	7(53.8)	11(37.9)	0.531
No	28(66.7)	6(46.2)	18(62.1)	

Table 4 - Natural history / outcomes for trisomy 13 and trisomy18.

Legend: n: absolute frequency; n%: relative frequency; p: statistical significance; **miscarriage: considering the outcome before 22 + 6 weeks, limit of viability at the Hospital de Clínicas de Porto Alegre; T13: trisomy 13; T18: trisomy 18. *Chi-Square test with adjusted residual analysis. Statistical significance was set at p≤0.05 for all analyses.

SOBRE A ORGANIZADORA

LAIS DAIENE COSMOSKI - Professora adjunta do Centro de Ensino Superior dos Campos Gerais (CESCAGE), nos cursos de Tecnologia em Radiologia e Bacharelado em Farmácia. Analista clínica no Laboratório do Hospital Geral da Unimed (HGU). Bacharel em Biomedicina pelas Universidades Integradas do Brasil (UniBrasil). Especialista em Circulação Extracorpórea pelo Centro Brasileiro de Ensinos Médicos (Cebramed) Mestre em Ciências Farmacêuticas pelo programa de Pôs Graduação em Ciências Farmacêuticas da UEPG. Possui experiência com o desenvolvimento de pesquisas na área de avaliação clínico/laboratorial de processos fisiopatológicos.

ÍNDICE REMISSIVO

Α

Acidente ofídico 183, 184, 185, 195, 196

Agentes comunitários de saúde 11, 46, 47, 70, 71, 72, 73, 80, 81

Aleitamento materno 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 239, 242, 244

Área carente de assistência médica 130

Assistência à saúde 130, 218

Atenção primária 3, 4, 6, 7, 8, 9, 28, 35, 43, 49, 50, 67, 71, 76, 81, 87, 127, 229

Avaliação da situação de saúde 2

C

Cuidado 7, 32, 33, 49, 71, 75, 81, 126, 221, 225, 229, 230, 232

D

Dano oxidativo 54, 56, 57

Dermatologia 130, 131, 132

Desmame 28, 29, 32, 33, 37, 39, 111

Doenças crônicas 2, 8, 19, 42, 43, 45, 46, 49, 53, 72, 85

Ε

Educação em saúde 70, 71, 72, 78, 79, 80, 81, 83, 85, 87, 178, 181, 182, 195 Epidemiologia 2, 7, 9, 26, 27, 32, 55, 153, 182, 196, 247 Esquistossomose 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182 Estimulação magnética transcraniana 89, 90, 91, 92, 93, 94, 95, 99 Estudante 41, 51, 93

G

Grupos de pesquisa 89, 91, 93, 94, 95, 96, 97, 98, 99

Н

Hipertensão 1, 5, 10, 12, 13, 14, 32, 42, 43, 44, 47, 48, 49, 50, 53, 54, 55, 57, 70, 72, 73, 77, 78, 80, 81, 83, 84, 154, 173, 231, 235

Indicadores de projetos de pesquisa e desenvolvimento 89 Insuficiência cardíaca 47, 143, 144, 148, 152, 153

K

Kanban 216, 219, 220, 221, 222, 223, 224, 225, 226, 227

L

Lean 216, 218, 220, 224, 226, 227, 228

M

Mapeamento geográfico 2, 6 Medicina de família e comunidade 9, 10, 44, 49, 132

Ν

Negros 53, 54, 55 Nutrição do adolescente 17

0

Ofidismo 183, 184, 185, 186, 187, 189, 190, 191, 192, 195, 196

P

Parasitose 171

Perfil epidemiológico 5, 32, 83, 85, 171, 174, 181, 183, 184, 186, 187, 192, 195, 196

Pesquisa 1, 6, 8, 9, 17, 19, 20, 21, 24, 26, 30, 31, 35, 36, 40, 41, 42, 45, 52, 53, 55, 59, 60, 61, 62, 65, 68, 70, 73, 75, 89, 91, 92, 93, 94, 95, 96, 97, 98, 99, 102, 118, 119, 121, 122, 124, 125, 145, 146, 151, 152, 164, 175, 181, 183, 186, 194, 219, 220, 238

Pesquisa sobre serviços de saúde 89

Preferências alimentares 17, 20

Projetos de pesquisa 9, 89

Projetos de pesquisa e desenvolvimento 89

Promoção da saúde 3, 8, 29, 71, 81, 116

R

Risco 3, 10, 11, 12, 13, 31, 32, 34, 39, 47, 48, 55, 56, 83, 106, 117, 153, 176, 178, 181, 193, 196, 235, 246

S

Saúde coletiva 14, 76, 80, 81, 83, 84, 88, 171, 216, 227 Saúde mental 40, 41, 99, 232 Serpentes 183, 184, 185, 189, 190, 193, 194, 195, 196, 197 Sistema de gerenciamentos de bases de dados 144 Superlotação hospitalar 216, 217, 224

T

Telemedicina 129, 130, 131, 132 Transplante cardíaco 143, 144, 150, 151, 152, 153, 154

U

Úlcera venosa 229, 230, 231, 232, 233 Unidade básica de saúde 1, 2, 6, 7, 8, 10, 32, 37, 42, 43, 45

٧

Vulnerabilidade em saúde 17

